This study is looking for healthy children and adolescents, ages 2 to 17 years old that are interested in getting a pneumonia vaccine. Most children get a pneumonia vaccine in the first year of life. This research study will be testing a new version of the pneumonia vaccine that is designed to protect your child against additional strains of pneumonia. This means your child will receive one dose of the updated version of the vaccine, PCV21, or your child will receive PCV20, the currently administered pneumonia vaccine in the U.S. You will be expected to accompany your child for 2 clinic visits that will include your child’s vaccine injection and 2 blood draws. You must complete two telephone visits as well. The study duration is 6 months. Your child may qualify for enrollment if they are healthy and are ages 7 months to 23 months, but have never had a pneumonia vaccine. Compensation will be provided. If you are interested in enrollment or need more information, please contact Alexis, Misty, or Sama at 205-638-2629. Email as well at mlpurser@uabmc.edu
Study Information:
- Are you 18-60 years of age living with HIV, and want to be a part of a vaccine study?
- Is your viral load suppressed/undetectable?
- Are you able to receive a vaccine?
- Are you generally healthy?
- Are you willing to temporarily stop taking antiretrovirals?
You may qualify for a study looking at testing an experimental HIV vaccine with an experimental adjuvant to see how the immune responses change among participants who do an antiretroviral analytical treatment interruption (ATI) compared to those who do not. Compensation at each study visit will be provided for time and travel. Transportation services are also available upon request. If interested, please email sspaulding@uabmc.edu.
• Are you 18-70 years of age living with HIV, and want to be a part of a curative study?
• Is your viral load suppressed/undetectable?
• Are you able to receive an infusion or injection?
• Are you generally healthy?
• Are you willing to temporarily stop taking antiretrovirals?
You may qualify for a HIV treatment study looking at an investigational way to effectively clear the HIV virus in areas of the body that standard antiretroviral treatment is unable to reach. You will receive one of two potential intervention methods. One intervention method is a broadly neutralizing antibody that is given to control growth of the HIV virus and to increase the body’s immune system response. The second intervention method is an injection (IL-15 Superagonist) designed to awaken the immune system, activate any dormant HIV virus, and then kill the virus. The duration of this study is approximately 84-112 weeks pending on which intervention method you receive. There is compensation at each study visit for time and travel.
Contact: If interested, please email kspraggins@uabmc.edu or call 205-934-9346
• Is your viral load suppressed/undetectable?
• Are you able to receive an infusion or injection?
• Are you generally healthy?
• Are you willing to temporarily stop taking antiretrovirals?
You may qualify for a HIV treatment study looking at an investigational way to effectively clear the HIV virus in areas of the body that standard antiretroviral treatment is unable to reach. You will receive one of two potential intervention methods. One intervention method is a broadly neutralizing antibody that is given to control growth of the HIV virus and to increase the body’s immune system response. The second intervention method is an injection (IL-15 Superagonist) designed to awaken the immune system, activate any dormant HIV virus, and then kill the virus. The duration of this study is approximately 84-112 weeks pending on which intervention method you receive. There is compensation at each study visit for time and travel.
Contact: If interested, please email kspraggins@uabmc.edu or call 205-934-9346
Are you:
• A woman on parole, probation, or recently released from prison or jail?
• A woman who has used drugs?
• Interested in learning about a way to protect yourself against HIV?
You may qualify for a paid research study at the University of Alabama at Birmingham, in partnership with Yale University.
• Participate in confidential study interviews at our research office.
• Earn $50 for each interview, up to $225 for participating in the study.
Fill out our contact survey at: https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_d7sAjr6GDsjiJng?Q_CHL=qr
Or you may call: (205) 934-2851 or Email: AthenaStudy@uabmc.edu
• A woman on parole, probation, or recently released from prison or jail?
• A woman who has used drugs?
• Interested in learning about a way to protect yourself against HIV?
You may qualify for a paid research study at the University of Alabama at Birmingham, in partnership with Yale University.
• Participate in confidential study interviews at our research office.
• Earn $50 for each interview, up to $225 for participating in the study.
Fill out our contact survey at: https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_d7sAjr6GDsjiJng?Q_CHL=qr
Or you may call: (205) 934-2851 or Email: AthenaStudy@uabmc.edu
Congenital CMV infection is the most common infection passed from the mother to baby during pregnancy. It is also the most common non-hereditary cause of hearing loss and brain damage in children. You or your child will have 3 injections, several months apart. You will have approximately 11 clinic visits over the 18 month study period. Saliva swabs, urine, and blood samples will be required. Compensation for participation is available. To learn more, visit CMVibeTrial.com or contact the UAB study team: 205-638-2629 or mlpurser@uabmc.edu
In a talk at UAB on March 6, the NIH director shared his thoughts on exceptional opportunities for science and young scientists — and highlighted several exciting UAB projects.
Have you had recurrent BV (bacterial vaginal infections) 2 or more times in the past 12 months? We are conducting a sexual partner study for treatment of the female and male sexual partners as a way to prevent BV. Medication at no cost to you. Couples can receive up to $300. Joy, 205-996-2780
